Opsidio

Executive Summary

Opsidio is a private, Phase 2 biotechnology company based in Boston, Massachusetts, focused on developing therapies for chronic inflammation and its severe consequences, including organ fibrosis. Founded in 2022, the company aims to address the high unmet need in fibrotic diseases, which affect millions of patients worldwide. While specific details on its pipeline are not publicly available, Opsidio's positioning in the inflammation and biologics space suggests it may be advancing antibody-based or biologic candidates targeting key fibrotic pathways. The company's stage indicates active clinical development, and its Boston location offers access to a strong life sciences ecosystem. However, as a private firm with limited disclosed data, the near-term outlook depends on progressing its lead program through Phase 2 and securing partnerships or funding to support later-stage trials.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Data Readout for Lead Candidate40% success
• Q4 2026Strategic Partnership or Licensing Deal50% success
• Q2 2026Series B or Later-Stage Financing Round70% success